Sanofi says FDA approves Sarclisa Escena subcutaneous formulation for multiple myeloma treatment in US
SNY•FDA approves Sarclisa Escena for multiple myeloma
Sanofi says the FDA cleared Sarclisa Escena, a subcutaneous isatuximab formulation, for multiple myeloma across all existing Sarclisa IV indications.
- The product becomes the first anticancer therapy in the US administered via an on-body injector, using Enable Injections’ CirCLIQ device.
- The Phase 3 IRAKLIA study showed non-inferior response rates versus IV Sarclisa, with fewer systemic administration reactions.
